KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBT (2018 - 2025)

Adaptive Biotechnologies' EBT history spans 8 years, with the latest figure at -$12.8 million for Q4 2025.

  • For Q4 2025, EBT rose 62.12% year-over-year to -$12.8 million; the TTM value through Dec 2025 reached -$57.9 million, up 63.72%, while the annual FY2025 figure was -$59.5 million, 62.75% up from the prior year.
  • EBT for Q4 2025 was -$12.8 million at Adaptive Biotechnologies, down from $10.3 million in the prior quarter.
  • Across five years, EBT topped out at $10.3 million in Q3 2025 and bottomed at -$69.5 million in Q4 2023.
  • The 5-year median for EBT is -$46.9 million (2024), against an average of -$42.3 million.
  • The largest annual shift saw EBT plummeted 89.88% in 2023 before it soared 132.06% in 2025.
  • A 5-year view of EBT shows it stood at -$61.4 million in 2021, then soared by 40.38% to -$36.6 million in 2022, then tumbled by 89.88% to -$69.5 million in 2023, then skyrocketed by 51.46% to -$33.7 million in 2024, then surged by 62.12% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's EBT are -$12.8 million (Q4 2025), $10.3 million (Q3 2025), and -$25.6 million (Q2 2025).